A three-pronged approach to waste composition determination.

Understanding solid waste composition has frequently been cited as one of the most valuable resources to those responsible for the proper management of solid waste. The unique contribution of this article lies in the fact that a waste characterisation study, conducted in a remote rural town in South Africa, was combined with an illegal dumping contents mapping and a household survey. This enabled researchers to gain a more thorough understanding of household waste management practices and challenges in this community, bridging the knowledge gap that is created when illegal dumping and household perceptions are omitted from waste characterisation studies in study areas where illegal dumping is an ongoing concern. The study therefore contributes to understanding the waste behaviour of households within the larger context of the town's waste management practices. Results indicate that, in order for municipalities to fully understand how to manage their waste, the contents of illegal dumping, where present, and household surveys should also be included in waste characterisation assessments.

Assessment of the induction of dormant ring stages in Plasmodium falciparum parasites by artemisone and artemisone entrapped in Pheroid vesicles in vitro.

The in vitro antimalarial activities of artemisone and artemisone entrapped in Pheroid vesicles were compared, as was their ability to induce dormancy in Plasmodium falciparum. There was no increase in the activity of artemisone entrapped in Pheroid vesicles against multidrug-resistant P. falciparum lines. Artemisone induced the formation of dormant ring stages similar to dihydroartemisinin. Thus, the Pheroid delivery system neither improved the activity of artemisone nor prevented the induction of dormant rings.

The effect of the Pheroid delivery system on the in vitro metabolism and in vivo pharmacokinetics of artemisone.

OBJECTIVES: The objectives were to determine the pharmacokinetics (PK) of artemisone and artemisone formulated in the Pheroid® drug delivery system in primates and to establish whether the formulation affects the in vitro metabolism of artemisone in human and monkey liver and intestinal microsomes. METHODS: For the PK study, a single oral dose of artemisone was administered to vervet monkeys using a crossover design. Plasma samples were analyzed by means of liquid chromatography-tandem mass spectrometry. For the in vitro metabolism study, clearance was determined using microsomes and recombinant CYP3A4 enzymes, and samples were analyzed by means of ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry. RESULTS: Artemisone and M1 plasma levels were unexpectedly low compared to those previously recorded in rodents and humans. The in vitro intrinsic clearance (CLint) of the reference formulation with monkey liver microsomes was much higher (1359.33 ± 103.24 vs 178.86 ± 23.42) than that of human liver microsomes. The in vitro data suggest that microsomal metabolism of artemisone is inhibited by the Pheroid delivery system. CONCLUSIONS: The in vivo results obtained in this study indicate that the Pheroid delivery system improves the PK profile of artemisone. The in vitro results indicate that microsomal metabolism of artemisone is inhibited by the Pheroid delivery system.